Effectiveness and safety of canakinumab in cryopyrin-associated periodic syndrome: a retrospective study in China
Canakinumab may be effective and tolerable for Chinese CAPS patients, helping to reduce the dosage of corticosteroids. However, additional trials on large samples are required to further evaluate its efficacy and safety in China.
Authors
- Xiaona Zhu
- Jun Yang (ORCID: https://orcid.org/0000-0002-7460-2800)
- Yanyan Huang (ORCID: https://orcid.org/0000-0003-4136-6044)
- Jiaqi Fan (ORCID: https://orcid.org/0009-0002-3541-7984)
- Tingyan He (ORCID: https://orcid.org/0000-0002-0222-2091)
- Zhi Yang (ORCID: https://orcid.org/0000-0003-2377-3113)
- Yongbin Xu (ORCID: https://orcid.org/0000-0003-2347-8114)
- Ying Luo (ORCID: https://orcid.org/0000-0002-6368-1937)
- Ruohang Weng
Institutions
- Shenzhen Children's Hospital (CN)
Publication Details
- Journal
- Pediatric Rheumatology
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1186/s12969-024-01023-w
- Citations
- 4
- Primary Topic
- Inflammasome and immune disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- National Natural Science Foundation of China